cAPPricorn-1: A clinical trial for people living with Cerebral Amyloid Angiopathy (CAA)
Summary
cAPPricorn-1 is researching an investigational medication called mivelsiran (Pronounced my-VEL-sur-an) to see if it's safe and effective. Participating in this trial is a chance to contribute to CAA research.
Mivelsiran is a type of medication called a RNAi therapeutic designed to lower the production of a specific protein called amyloid precusor protein (APP)in the brain. this reduction may potential reduce the harmful buildup of harmful amyloid proteins and the brain's blood vessels and potentially slow down the worsening of CAA.
During the treatment period of cAPPricorn-1, you will have study visits about once every 3 months for a total of 12 visits over 2 years. With the optional 18-month open-label extension period, you would have an additional 5 study visits. There will also be a follow-up visit 1 year after the end of treatment, whether it be the double-blind treatment period or the open-label
extension period.
Eligibility
Eligible ages: 50 to 90
Inclusion criteria:
There are 2 type of CAA: Sporadic CAA or Dutch-type CAA. You must have a diagnosis of either to participate.
In addition, specific to each type, people who can participate are people:
With Sporadic CAA who are:
-50 years of age or older
-Have recedived a diagnosis of CAA from their doctor
With Dutch-type CAA who are:
-30 years of age or older
-Have known gene mutation for Dutch-typeCAA
Additional criteria are assessed by the study team.
Exclusion criteria:
People not eligible:
-People who have moderate to severe Alzheimer's disease
-History of previous intracranial bleeding (brain bleed) within 3 months
-no anti-platelet therapy or anti-coagulant therapy (blood thinners). Aspirin is allowed.
-must be able to have a lumbar puncture (spinal tap). No spinal problems.
-No significant heart problems
-No high blood pressure with a systolic greater than 150mmHg and diastolic greater than 90mmHg
-No attempted suicide
Other additional exclusions will be assessed by the study team
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Diagnosis of CAA documented by a physician
Principal investigator:
Eric Smith
Clinical trial:
Yes
REB-ID:
REB24-1030
External links